Reported Earlier, Scilex Secures 5-Year Term Of $100M In Royalty-Based Financing For Non-Opioid Pain Management Expansion
Portfolio Pulse from Benzinga Newsdesk
Scilex has secured a 5-year term of $100 million in royalty-based financing to expand its non-opioid pain management solutions. The funds will be used to repay an $85 million loan from Oramed Pharmaceuticals and for general corporate purposes.
June 12, 2024 | 7:32 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Oramed Pharmaceuticals will receive repayment of an $85M loan from Scilex, improving its liquidity position.
The repayment of the $85M loan by Scilex will improve Oramed Pharmaceuticals' liquidity, potentially allowing for reinvestment or other financial maneuvers.
CONFIDENCE 85
IMPORTANCE 70
RELEVANCE 50
POSITIVE IMPACT
Scilex secures $100M in financing to expand non-opioid pain management, repay $85M loan from Oramed Pharmaceuticals, and support general corporate purposes.
The $100M financing will help Scilex repay its existing $85M loan, improving its financial stability. The remaining $15M will support general corporate purposes, potentially driving growth in its non-opioid pain management segment.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100